An observational study in Hepatocellular Carcinoma, sponsored by Beijing 302 Hospital. Status unknown at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-27.
Sponsored by Beijing 302 Hospital · Observational
The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.
3,251 studies on the registry are indexed under Carcinoma, Hepatocellular; 974 are open to participants now.
This study's planned enrollment of 60 is below the median of 200 across 769 observational studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →Beijing 302 Hospital is the lead sponsor of 88 studies on the registry; 31 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The small HCC patients with decompensated cirrhosis who refused or were ineligible for other treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.
Overall survival time
OS is calculated starting from the date of SBRT to the date of the final follow-up or demise of the patients.
Time frame: From date of randomization until the date of death from any cause, assessed up to 36 months
Progression-free survival time
PFS is estimated starting from the date of SBRT to the date of disease progression or patient death.
Time frame: From date of randomization until the date of disease progression or date of death from any cause, whichever came first, assessed up to 36 months
Local control time
LC is defined starting from the date of SBRT to the date of treated-lesion progression or patient death.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
Radiation-induced liver injury rates
Time frame: From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.
Adverse reaction
Time frame: From the date of radiotherapy completion until the 4 months after therapy,up to 6 months.
Plan to share: Undecided
Started Aug 2020 (actual). Primary completion is estimated for Aug 2023, 36 months after the start.
Of 273 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 112. This study's planned 36 months is below that.
Counting every sponsor, half of 313 studies reached it within 50 months; a quarter within 32 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing 302 Hospital